EUVIMEDEUVIMED entdecken
Open Access

Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond

Jennifer K Lue, Owen A O'Connor, Francesco Bertoni

Annals of Lymphoma · 2020

DOI: 10.21037/aol-20-20 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Lymphoma, 2020. Verfasst von Jennifer K Lue und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, Columbia University Medical Center, Center for Lymphoid Malignancies, New York, NY, USA. Die Arbeit wurde bisher 15-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Swiss National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Marginal zone lymphoma (MZL) represents a group of three distinct though overlapping lymphoid malignancies that includes extranodal, nodal and splenic marginal lymphoma. MZL patients usually present an indolent clinical course, although the disease remains largely incurable, save early stage disease that might be irradiated. Therapeutic advances have been limited due to the small patient population, and have largely been adapted from other indolent lymphomas. Here, we discuss the numerous targets and pathways which may offer the prospect of directly inhibiting the mechanisms identified promoting and sustaining marginal zone lymphomagenesis. In particular, we focus on the agents that may have at least a theoretical application in the disease. Various dysregulated pathways converge to produce an overarching stimulation of nuclear factor κB (NF-κB) and the MYD88-IRAK4 axis, which can be thus leveraged or targeting B-cell receptor signaling through BTK inhibitors (such as ibrutinib, zanubrutinib, acalabrutinib) and PI3K inhibitors (such as idelalisib, copanlisib, duvelisib umbralisib) or via more novel agents in development such as MALT1 inhibitors, SMAC mimetics, NIK inhibitors, IRAK4 or MYD88 inhibitors. NOTCH signaling is also crucial for marginal zone cells, but no clinical data are available with NOTCH inhibitors such as the γ-secretase inhibitor PF-03084014 or the NICD inhibitor CB-103. The hypermethylation phenotype, the overexpression of the PRC2-complex or the presence of TET2 mutations reported in MZL subsets make epigenetic agents (demethylating agents, EZH2 inhibitors, HDAC inhibitors) also potential therapeutic tools for MZL patients.

Schlagwörter

Stichwörter der Autor:innen

MYD88Marginal zone lymphoma (MZL)NOTCHPI3Kmucosa-associated lymphoid tissue (MALT)nuclear factor κB (NF-κB)

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Medicine, Columbia University Medical Center, Center for Lymphoid Malignancies, New York, NY, USA.
  • Division of Hematology and Oncology, Program for T-Cell Lymphoma Research, University of Virginia Cancer Center, Charlottesville, VA, USA.
  • institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
  • Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.

Förderung

  • Swiss National Science Foundation

Zitieren

APA

Lue, J. K., O'Connor, O. A., & Bertoni, F. (2020). Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond. Annals of Lymphoma. https://doi.org/10.21037/aol-20-20

Vancouver

Lue JK, O'Connor OA, Bertoni F. Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond. Annals of Lymphoma. 2020. doi:10.21037/aol-20-20

BibTeX
@article{Lue2020,
  author = {Lue, Jennifer K and O'Connor, Owen A and Bertoni, Francesco},
  title = {Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond},
  journal = {Annals of Lymphoma},
  year = {2020},
  doi = {10.21037/aol-20-20}
}
Kostenlos starten →